S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

NASDAQ:AGTC - Applied Genetic Technologies Stock Price, Forecast & News

$5.69
+0.14 (+2.52 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$5.45
Now: $5.69
$5.75
50-Day Range
$4.13
MA: $6.42
$9.86
52-Week Range
$2.52
Now: $5.69
$10.42
Volume713,419 shs
Average Volume2.20 million shs
Market Capitalization$103.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.82
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGTC
CUSIPN/A
Phone386-462-2204

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$41.69 million
Book Value$3.30 per share

Profitability

Net Income$-2,010,000.00

Miscellaneous

Employees78
Market Cap$103.67 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive AGTC News and Ratings via Email

Sign-up to receive the latest news and ratings for AGTC and its competitors with MarketBeat's FREE daily newsletter.


Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Corp (NASDAQ:AGTC) posted its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.06. Applied Genetic Technologies had a negative return on equity of 26.07% and a negative net margin of 4.81%. View Applied Genetic Technologies' Earnings History.

When is Applied Genetic Technologies' next earnings date?

Applied Genetic Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Applied Genetic Technologies.

What price target have analysts set for AGTC?

6 brokers have issued 12-month price objectives for Applied Genetic Technologies' shares. Their forecasts range from $10.00 to $25.00. On average, they expect Applied Genetic Technologies' stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 190.0% from the stock's current price. View Analyst Price Targets for Applied Genetic Technologies.

What is the consensus analysts' recommendation for Applied Genetic Technologies?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Genetic Technologies.

What are Wall Street analysts saying about Applied Genetic Technologies stock?

Here are some recent quotes from research analysts about Applied Genetic Technologies stock:
  • 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (11/19/2019)
  • 2. Chardan Capital analysts commented, "We now upgrade AGTC to the opportunity represented by a company: (1) now trading at 64% of 30 March 2019 cash, and (2) with important phase I/II data through 1H20 on 3 different programs (ACHM-A3, ACHM-B3, XLRP). We continue to flag the delays AGTC has had over the years in reporting datasets in achromatopsia A3 (ACHM-A3), achromatopsia X- linked retinitis pigmentosa (XLRP). The delays occurred as innovative companies like MeiraGTx (Buy, a Therapeutics (acquired by unrated Biogen) made progress with competing inherited retinal disease franchises (see research below). Despite the AGTC delays, we note that good science sometimes takes time to develop; and, industry participants recognize the soundness of AGTC’s science and broader capabilities, even if execution has been slow." (9/3/2019)
  • 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating $12 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Currently the ACHM programs contribute 55% to our valuation, with the remaining 45% coming from XLRP. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (7/25/2019)

Has Applied Genetic Technologies been receiving favorable news coverage?

News coverage about AGTC stock has been trending somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Applied Genetic Technologies earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Applied Genetic Technologies.

Are investors shorting Applied Genetic Technologies?

Applied Genetic Technologies saw a increase in short interest in January. As of January 31st, there was short interest totalling 527,700 shares, an increase of 234.2% from the January 15th total of 157,900 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 3.8% of the shares of the company are sold short. View Applied Genetic Technologies' Current Options Chain.

Who are some of Applied Genetic Technologies' key competitors?

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Anavex Life Sciences (AVXL), Micron Technology (MU), AcelRx Pharmaceuticals (ACRX), Chiasma (CHMA), Nabriva Therapeutics (NBRV), Ocular Therapeutix (OCUL) and Opko Health (OPK).

Who are Applied Genetic Technologies' key executives?

Applied Genetic Technologies' management team includes the folowing people:
  • Ms. Susan B. Washer, Pres, CEO & Director (Age 58)
  • Mr. William A. Sullivan, Chief Financial Officer (Age 48)
  • Dr. Matthew Feinsod, Interim Chief Medical Officer (Age 48)
  • Dr. Nicholas Muzyczka, Co-Founder
  • Dr. Barry J. Byrne, Co-Founder

Who are Applied Genetic Technologies' major shareholders?

Applied Genetic Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.67%), Acadian Asset Management LLC (3.87%), Ikarian Capital LLC (1.10%), Colony Group LLC (0.73%), Jacobs Levy Equity Management Inc. (0.57%) and Marshall Wace LLP (0.44%). Company insiders that own Applied Genetic Technologies stock include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan and William Aliski. View Institutional Ownership Trends for Applied Genetic Technologies.

Which major investors are selling Applied Genetic Technologies stock?

AGTC stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Colony Group LLC, Bank of America Corp DE, Alambic Investment Management L.P. and Wedbush Securities Inc.. View Insider Buying and Selling for Applied Genetic Technologies.

Which major investors are buying Applied Genetic Technologies stock?

AGTC stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Renaissance Technologies LLC, Russell Investments Group Ltd., Oxford Asset Management LLP, Jacobs Levy Equity Management Inc., Marshall Wace North America L.P. and Acadian Asset Management LLC. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan and William Aliski. View Insider Buying and Selling for Applied Genetic Technologies.

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $5.69.

How big of a company is Applied Genetic Technologies?

Applied Genetic Technologies has a market capitalization of $103.67 million and generates $41.69 million in revenue each year. The biotechnology company earns $-2,010,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Applied Genetic Technologies employs 78 workers across the globe.View Additional Information About Applied Genetic Technologies.

What is Applied Genetic Technologies' official website?

The official website for Applied Genetic Technologies is http://www.agtc.com/.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.


MarketBeat Community Rating for Applied Genetic Technologies (NASDAQ AGTC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  391 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  649
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel